Premium
Combination chemotherapy with L‐asparaginase (EC‐2) using P1798 lymphosarcoma
Author(s) -
Mashburn L. T.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1971)28:5<1321::aid-cncr2820280535>3.0.co;2-i
Subject(s) - medicine , vincristine , asparaginase , chemotherapy , cytosine , fluorouracil , combination chemotherapy , gastroenterology , pharmacology , oncology , leukemia , cyclophosphamide , lymphoblastic leukemia , biology , biochemistry , dna
A variety of chemotherapeutic agents were examined in combination with asparaginase (EC‐2) using P1798 lymphosarcoma in BALB/c mice as a test system with the aim of attaining remissions of long duration. Since it is possible to obtain permanent remissions in this system with large doses of EC‐2, the level of enzyme administered was reduced so that the experimental results could be more closely correlated to the human disease response. The best results were obtained when asparaginase was given as the primary therapy with the other agents given subsequently. Second agents administered simultaneously with EC‐2 were not as beneficial as sequential or alternate therapy. Triple, sequential therapy was found superior to double therapy, and high incidences of permanent remissions were obtained when azotomycin (71%), cytosine arabinoside (78%), Cytoxan (64%), or 5‐Fluorouracil (78%) were given subsequent to EC‐2 but before vincristine.